Immunic’s Vidofludimus Cuts Gadolinium, T2 Lesions and SELs in Phase 2 MS Trial
Results from the CALIPER Phase 2 trial in progressive multiple sclerosis showed that Vidofludimus calcium significantly reduced both gadolinium-enhancing and T2 MRI lesions. A 45 mg dose also delivered a statistically significant decrease in slowly expanding lesions, indicating potential efficacy against chronic compartmentalized inflammation.
1. Phase 2 CALIPER Trial Results
Immunic’s CALIPER Phase 2 trial in progressive multiple sclerosis evaluated Vidofludimus calcium’s effect on inflammatory lesions. MRI outcomes showed significant reductions in both gadolinium-enhancing and T2 lesions, underscoring the drug’s potential to mitigate acute disease activity.
2. Impact on Acute and Chronic Inflammation
Multiple sclerosis involves acute inflammatory attacks driven by peripheral immune cells and a second phase of chronic compartmentalized inflammation inside the brain. Vidofludimus calcium demonstrated efficacy in reducing lesions associated with active inflammation, addressing one component of disease pathology.
3. SEL Reduction at 45mg Dose
Chronic compartmentalized inflammation manifests as slowly expanding lesions (SELs) detectable with advanced MRI markers. A 45 mg dose of Vidofludimus calcium achieved a statistically significant decline in SEL count compared to placebo, indicating potential to target long-term disease progression.